## Paul Harrison

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9388812/publications.pdf

Version: 2024-02-01

227 21,917 63 141 papers citations h-index g-index

239 239 25425
all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Rare missense variants in Tropomyosinâ€4 (TPM4) are associated with platelet dysfunction, cytoskeletal defects, and excessive bleeding. Journal of Thrombosis and Haemostasis, 2022, 20, 478-485.	3.8	3
2	Analysis of preplatelets and their barbell platelet derivatives by imaging flow cytometry. Blood Advances, 2022, 6, 2932-2946.	5.2	9
3	CD14-positive extracellular vesicles in bronchoalveolar lavage fluid as a new biomarker of acute respiratory distress syndrome. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2022, 322, L617-L624.	2.9	11
4	<i>Platelets</i> editorial 2022: transitioning. Platelets, 2022, 33, 1-2.	2.3	0
5	Feasibility of a mean platelet volume standard: an international council for standardization in hematology (ICSH) inter-laboratory study. Platelets, 2022, 33, 1159-1167.	2.3	3
6	Platelets and open access – a new era dawns. Platelets, 2022, 33, 807-808.	2.3	1
7	Expert opinion on the use of platelet secretion assay for the diagnosis of inherited platelet function disorders: Communication from the ISTH SSC Subcommittee on Platelet Physiology. Journal of Thrombosis and Haemostasis, 2022, 20, 2127-2135.	3.8	6
8	Characteristics of L-PRP preparations for treating Achilles tendon rupture within the PATH-2 study. Platelets, 2021, 32, 273-279.	2.3	8
9	Editorial Platelets 2021: toward a brighter year. Platelets, 2021, 32, 1-2.	2.3	5
10	Heparin resistance in severe thermal injury: a prospective cohort study. Burns and Trauma, 2021, 9, tkab032.	4.9	5
11	The state of the art and future of PRP therapy. Platelets, 2021, 32, 150-151.	2.3	1
12	The ISTH bleeding assessment tool as predictor of bleeding events in inherited platelet disorders: Communication from the ISTH SSC Subcommittee on Platelet Physiology. Journal of Thrombosis and Haemostasis, 2021, 19, 1364-1371.	3.8	19
13	Plateletâ€enhanced plasma: Characterization of a novel candidate resuscitation fluid's extracellular vesicle content, clotting parameters, and thrombin generation capacity. Transfusion, 2021, 61, 2179-2194.	1.6	7
14	Effect of Platelet-Rich Plasma Injection vs Sham Injection on Tendon Dysfunction in Patients With Chronic Midportion Achilles Tendinopathy. JAMA - Journal of the American Medical Association, 2021, 326, 137.	7.4	41
15	Consensus recommendations on flow cytometry for the assessment of inherited and acquired disorders of platelet number and function: Communication from the ISTH SSC Subcommittee on Platelet Physiology. Journal of Thrombosis and Haemostasis, 2021, 19, 3193-3202.	3.8	20
16	Traumatic injury is associated with reduced deoxyribonuclease activity and dysregulation of the actin scavenging system. Burns and Trauma, 2021, 9, tkab001.	4.9	17
17	Multicentre, longitudinal, observational cohort study to examine the relationship between neutrophil function and sepsis in adults and children with severe thermal injuries: a protocol for the Scientific Investigation of the Biological Pathways Following Thermal Injury-2 (SIFTI-2) study. BMJ Open. 2021. 11. e052035.	1.9	2
18	A brief history of nearly EVâ€erything – The rise and rise of extracellular vesicles. Journal of Extracellular Vesicles, 2021, 10, e12144.	12.2	150

#	Article	IF	Citations
19	Randomized controlled trial protocol to investigate the antiplatelet therapy effect on extracellular vesicles (AFFECT EV) in acute myocardial infarction. Platelets, 2020, 31, 26-32.	2.3	18
20	Dysregulation of the actin scavenging system and inhibition of DNase activity following severe thermal injury. British Journal of Surgery, 2020, 107, 391-401.	0.3	18
21	Inflammaging and platelet hyperreactivity: A new therapeutic target?. Journal of Thrombosis and Haemostasis, 2020, 18, 3-5.	3.8	10
22	Ticagrelor attenuates the increase of extracellular vesicle concentrations in plasma after acute myocardial infarction compared to clopidogrel. Journal of Thrombosis and Haemostasis, 2020, 18, 609-623.	3.8	46
23	<i>Platelets</i> : the next decade. Platelets, 2020, 31, 1-2.	2.3	11
24	Validation of the ISTH/SSC bleeding assessment tool for inherited platelet disorders: A communication from the Platelet Physiology SSC. Journal of Thrombosis and Haemostasis, 2020, 18, 732-739.	3.8	64
25	Platelet count and disease – editorial policy. Platelets, 2020, 31, 969-970.	2.3	5
26	Editorial policy during the lockdown. Platelets, 2020, 31, 411-411.	2.3	2
27	Studies on platelet rich plasma - new editorial policy for "Platelets― Platelets, 2020, 31, 281-282.	2.3	11
28	Appropriation of $GPlb\hat{l}\pm$ from platelet-derived extracellular vesicles supports monocyte recruitment in systemic inflammation. Haematologica, 2020, 105, 1248-1261.	3.5	65
29	Impact of plasma viscosity on microcirculatory flow after traumatic haemorrhagic shock: A prospective observational study. Clinical Hemorheology and Microcirculation, 2019, 71, 71-82.	1.7	8
30	Comparison of nine platelet function tests used to determine responses to different aspirin dosages in people with type 2 diabetes. Platelets, 2019, 30, 521-529.	2.3	17
31	Traumatic Injury and Exposure to Mitochondrial-Derived Damage Associated Molecular Patterns Suppresses Neutrophil Extracellular Trap Formation. Frontiers in Immunology, 2019, 10, 685.	4.8	25
32	Platelet Counting. , 2019, , 581-591.		3
33	Clinical Tests of Platelet Function. , 2019, , 593-608.		1
34	<i>Platelets</i> – the second growth cycle. Platelets, 2019, 30, 1-1.	2.3	13
35	Therapeutic Platelet-Rich Plasma in Wound Healing. , 2019, , 1161-1171.		3
36	Platelet rich plasma injection for acute Achilles tendon rupture: PATH-2 randomised, placebo controlled, superiority trial. BMJ: British Medical Journal, 2019, 367, l6132.	2.3	51

#	Article	IF	Citations
37	Ability of Platelet-Derived Extracellular Vesicles to Promote Neutrophil-Endothelial Cell Interactions. Inflammation, 2019, 42, 290-305.	3.8	58
38	Tspan18 is a novel regulator of the Ca2+ channel Orai1 and von Willebrand factor release in endothelial cells. Haematologica, 2019, 104, 1892-1905.	3.5	16
39	Evaluation of the Total Thrombus-Formation System (T-TAS): application to human and mouse blood analysis. Platelets, 2019, 30, 893-900.	2.3	19
40	Investigation of the contribution of an underlying platelet defect in women with unexplained heavy menstrual bleeding. Platelets, 2019, 30, 56-65.	2.3	9
41	Platelet-rich plasma injection for adults with acute Achilles tendon rupture: the PATH-2 RCT. Efficacy and Mechanism Evaluation, 2019, 6, 1-98.	0.7	8
42	Standardization of extracellular vesicle measurements by flow cytometry through vesicle diameter approximation. Journal of Thrombosis and Haemostasis, 2018, 16, 1236-1245.	3.8	130
43	Platelets—Joining the 400 club. Platelets, 2018, 29, 1-1.	2.3	9
44	Maintenance of murine platelet homeostasis by the kinase Csk and phosphatase CD148. Blood, 2018, 131, 1122-1144.	1.4	35
45	Thromboelastometry and Platelet Function during Acclimatization to High Altitude. Thrombosis and Haemostasis, 2018, 118, 063-071.	3.4	30
46	The contribution of leucocytes to the antimicrobial activity of platelet-rich plasma preparations: A systematic review. Platelets, 2018, 29, 9-20.	2.3	22
47	Endotheliopathy of Trauma is an on-Scene Phenomenon, and is Associated with Multiple Organ Dysfunction Syndrome: A Prospective Observational Study. Shock, 2018, 49, 420-428.	2.1	87
48	Platelet count: A predictor of sepsis and mortality in severe burns. Burns, 2018, 44, 288-297.	1.9	33
49	Poor microcirculatory flow dynamics are associated with endothelial cell damage and glycocalyx shedding after traumatic hemorrhagic shock. Journal of Trauma and Acute Care Surgery, 2018, 84, 81-88.	2.1	68
50	Soluble GPVI is elevated in injured patients: shedding is mediated by fibrin activation of GPVI. Blood Advances, 2018, 2, 240-251.	5.2	41
51	Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. Journal of Extracellular Vesicles, 2018, 7, 1535750.	12.2	6,961
52	Laboratory monitoring of P2Y12 inhibitors: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2018, 16, 2341-2346.	3.8	11
53	Summary of the ISEV workshop on extracellular vesicles as disease biomarkers, held in Birmingham, UK, during December 2017. Journal of Extracellular Vesicles, 2018, 7, 1473707.	12.2	60
54	The use of platelets in regenerative medicine and proposal for a new classification system: guidance from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2018, 16, 1895-1900.	3.8	101

#	Article	IF	CITATIONS
55	Neutrophil Dysfunction, Immature Granulocytes, and Cell-free DNA are Early Biomarkers of Sepsis in Burn-injured Patients. Annals of Surgery, 2017, 265, 1241-1249.	4.2	139
56	Prothrombin Loading of Vascular Smooth Muscle Cell–Derived Exosomes Regulates Coagulation and Calcification. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, e22-e32.	2.4	80
57	Vesikel in der Natur und im Labor: die AufklÄ <b>r</b> ung der biologischen Eigenschaften und die Synthese zunehmend komplexer synthetischer Vesikel. Angewandte Chemie, 2017, 129, 3188-3208.	2.0	10
58	Platelets – A fine balance. Platelets, 2017, 28, 1-1.	2.3	10
59	Monocyte Subsets Coregulate Inflammatory Responses by Integrated Signaling through TNF and IL-6 at the Endothelial Cell Interface. Journal of Immunology, 2017, 198, 2834-2843.	0.8	77
60	From platelet dust to gold dust: physiological importance and detection of platelet microvesicles. Platelets, 2017, 28, 211-213.	2.3	24
61	Platelet responses to agonists in a cohort of highly characterised platelet donors are consistent over time. Vox Sanguinis, 2017, 112, 18-24.	1.5	14
62	Platelet-Rich Plasma in Regenerative Medicine. , 2017, , 1403-1416.		5
63	Comparison of multiple electrode aggregometry with lumiâ€aggregometry for the diagnosis of patients with mild bleeding disorders. Journal of Thrombosis and Haemostasis, 2017, 15, 2045-2052.	3.8	31
64	Platelet rich Plasma in Achilles Tendon Healing 2 (PATH-2) trial: protocol for a multicentre, participant and assessor-blinded, parallel-group randomised clinical trial comparing platelet-rich plasma (PRP) injection versus placebo injection for Achilles tendon rupture. BMJ Open, 2017, 7, e018135.	1.9	16
65	Changes in novel haematological parameters following thermal injury: A prospective observational cohort study. Scientific Reports, 2017, 7, 3211.	3.3	17
66	Vesicles in Nature and the Laboratory: Elucidation of Their Biological Properties and Synthesis of Increasingly Complex Synthetic Vesicles. Angewandte Chemie - International Edition, 2017, 56, 3142-3160.	13.8	65
67	Microvesicles in vascular homeostasis and diseases. Thrombosis and Haemostasis, 2017, 117, 1296-1316.	3.4	193
68	Changes in the pattern of plasma extracellular vesicles after severe trauma. PLoS ONE, 2017, 12, e0183640.	2.5	37
69	Platelet Function Tests., 2017,, 559-570.		2
70	Prehospital immune responses and development of multiple organ dysfunction syndrome following traumatic injury: A prospective cohort study. PLoS Medicine, 2017, 14, e1002338.	8.4	94
71	Endotheliopathy is associated with higher levels of cell-free DNA following major trauma: A prospective observational study. PLoS ONE, 2017, 12, e0189870.	2.5	33
72	Randomized controlled trial comparing impact on platelet reactivity of twiceâ€daily with onceâ€daily aspirin in people with Type 2 diabetes. Diabetic Medicine, 2016, 33, 224-230.	2.3	51

#	Article	IF	CITATIONS
73	Studies on Mean Platelet Volume (MPV) – New Editorial Policy. Platelets, 2016, 27, 605-606.	2.3	59
74	Whole exome sequencing identifies genetic variants in inherited thrombocytopenia with secondary qualitative function defects. Haematologica, 2016, 101, 1170-1179.	3.5	119
75	Platelet type von Willebrand disease and registry report: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2016, 14, 411-414.	3.8	26
76	Platelets– maintaining the flow. Platelets, 2016, 27, 1-1.	2.3	10
77	A review of platelet secretion assays for the diagnosis of inherited platelet secretion disorders. Thrombosis and Haemostasis, 2015, 114, 14-25.	3.4	82
78	Thrombin generation and procoagulant microparticle profiles after acute trauma. Journal of Trauma and Acute Care Surgery, 2015, 79, 726-731.	2.1	45
79	Extracellular vesicles, tissue factor, cancer and thrombosis – discussion themes of the ISEV 2014 Educational Day. Journal of Extracellular Vesicles, 2015, 4, 26901.	12.2	69
80	Platelets: The end of an era, start of a new beginning. Platelets, 2015, 26, 1-1.	2.3	11
81	Relationship between ADAMTS13 activity, von Willebrand factor antigen levels and platelet function in the early and late phases after TIA or ischaemic stroke. Journal of the Neurological Sciences, 2015, 348, 35-40.	0.6	28
82	Effect of platelet-rich plasma on healing tissues in acute ruptured Achilles tendon: a human immunohistochemistry study. Lancet, The, 2015, 385, S19.	13.7	59
83	The role of platelets in the recruitment of leukocytes during vascular disease. Platelets, 2015, 26, 507-520.	2.3	146
84	Special issue of Platelets in celebration of Stan Heptinstall, founder and Editor-in-Chief (1990–2015). Platelets, 2015, 26, 377-377.	2.3	1
85	Diagnosis of inherited platelet function disorders: guidance from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2015, 13, 314-322.	3.8	220
86	Levels of procoagulant microvesicles are elevated after traumatic injury and platelet microvesicles are negatively correlated with mortality. Journal of Extracellular Vesicles, 2014, 3, 25625.	12.2	42
87	Short bowel syndrome and clopidogrel non-responsiveness: a new indication for platelet aggregometry?. BMJ Case Reports, 2014, 2014, bcr2013202241-bcr2013202241.	0.5	0
88	Prospective observational cohort study of the association between thromboelastometry, coagulation and platelet parameters and bleeding in patients with haematological malignancies―The <scp>ATHENA</scp> study. British Journal of Haematology, 2014, 166, 581-591.	2.5	41
89	Particle size distribution of exosomes and microvesicles determined by transmission electron microscopy, flow cytometry, nanoparticle tracking analysis, and resistive pulse sensing. Journal of Thrombosis and Haemostasis, 2014, 12, 1182-1192.	3.8	698
90	Platelet counting with the BD Accuri <sup>TM</sup> C6 flow cytometer. Platelets, 2014, 25, 175-180.	2.3	30

#	Article	IF	Citations
91	Diagnosis of suspected inherited platelet function disorders: results of a worldwide survey. Journal of Thrombosis and Haemostasis, 2014, 12, 1562-1569.	3.8	139
92	Procoagulant and plateletâ€derived microvesicle absolute counts determined by flow cytometry correlates with a measurement of their functional capacity. Journal of Extracellular Vesicles, 2014, 3, .	12.2	27
93	CLEC-2 expression is maintained on activated platelets and on platelet microparticles. Blood, 2014, 124, 2262-2270.	1.4	104
94	Testing Platelet Function. Hematology/Oncology Clinics of North America, 2013, 27, 411-441.	2.2	52
95	Clinical Tests of Platelet Function. , 2013, , 519-545.		9
96	Platelet Counting. , 2013, , 547-557.		5
97	The role of platelet-rich plasma in tissue regeneration. Platelets, 2013, 24, 173-182.	2.3	175
98	Recommendations for the standardization of light transmission aggregometry: a consensus of the working party from the platelet physiology subcommittee of SSC/ISTH. Journal of Thrombosis and Haemostasis, 2013, 11, 1183-1189.	3.8	398
99	Advances in the monitoring of anti-P2Y12therapy. Platelets, 2012, 23, 510-525.	2.3	22
100	The Accuracy of Platelet Counting in Thrombocytopenic Blood Samples Distributed by the UK National External Quality Assessment Scheme for General Haematology. American Journal of Clinical Pathology, 2012, 137, 65-74.	0.7	34
101	Evaluation of the INNOVANCE PFA P2Y test cartridge: Sensitivity to P2Y <sub>12</sub> blockade and influence of anticoagulant. Platelets, 2012, 23, 106-115.	2.3	32
102	Classification, Functions, and Clinical Relevance of Extracellular Vesicles. Pharmacological Reviews, 2012, 64, 676-705.	16.0	1,429
103	A flow cytometric method for platelet counting in platelet concentrates. Transfusion, 2012, 52, 173-180.	1.6	8
104	Invisible vesicles swarm within the iceberg. Journal of Thrombosis and Haemostasis, 2012, 10, 916-918.	3.8	21
105	Aspirin twice a day keeps new COX-1 at bay. Journal of Thrombosis and Haemostasis, 2012, 10, 1217-1219.	3.8	20
106	Measurement of circulating cell-derived microparticles by flow cytometry: Sources of variability within the assay. Thrombosis Research, 2011, 127, 370-377.	1.7	178
107	Guidelines for the laboratory investigation of heritable disorders of platelet function. British Journal of Haematology, 2011, 155, 30-44.	2.5	307
108	Beware of being caught on the rebound. Journal of Thrombosis and Haemostasis, 2011, 9, 21-23.	3.8	9

#	Article	IF	CITATIONS
109	Differential contributions of monocyte―and plateletâ€derived microparticles towards thrombin generation and fibrin formation and stability. Journal of Thrombosis and Haemostasis, 2011, 9, 2251-2261.	3.8	153
110	Sizing and phenotyping of cellular vesicles using Nanoparticle Tracking Analysis. Nanomedicine: Nanotechnology, Biology, and Medicine, 2011, 7, 780-788.	3.3	1,068
111	Syncytiotrophoblast Microvesicles Released from Pre-Eclampsia Placentae Exhibit Increased Tissue Factor Activity. PLoS ONE, 2011, 6, e26313.	2.5	69
112	The influence of citrate concentrations on PFA-100 closure times, platelet hyper-reactivity and aspirin monitoring. Thrombosis Research, 2010, 126, e137-e138.	1.7	4
113	Evaluation of the Impact-R for monitoring the platelet storage lesion. Platelets, 2009, 20, 1-6.	2.3	15
114	Screening Tests of Platelet Function: Update on Their Appropriate Uses for Diagnostic Testing. Seminars in Thrombosis and Hemostasis, 2009, 35, 150-157.	2.7	66
115	Evaluation of the PDQâ,,¢ centrifuge for preparing platelet rich, platelet poor and platelet free plasma samples for light transmission aggregometry and microparticle measurement. Platelets, 2009, 20, 610-612.	2.3	4
116	Microparticle sizing by dynamic light scattering in freshâ€frozen plasma. Vox Sanguinis, 2009, 96, 206-212.	1.5	168
117	Measurement of phosphatidylserine exposure during storage of platelet concentrates using the novel probe lactadherin: a comparison study with annexin V. Transfusion, 2009, 49, 99-107.	1.6	54
118	Markers of platelet activation and apoptosis during storage of apheresis―and buffy coat–derived platelet concentrates for 7 days. Transfusion, 2009, 49, 108-117.	1.6	77
119	Rapid and accurate method for the von Willebrand factor ristocetin cofactor assay using 96â€well microtiter plates. Journal of Thrombosis and Haemostasis, 2009, 7, 1226-1228.	3.8	4
120	Genetics of platelet reactivity in normal, healthy individuals. Journal of Thrombosis and Haemostasis, 2009, 7, 2116-2122.	3.8	37
121	Call for contributions to the new Methods section in <i>Platelets</i> . Platelets, 2009, 20, 445-445.	2.3	0
122	Lack of association between aspirin responsiveness and seven candidate gene haplotypes in patients with symptomatic vascular disease. Thrombosis and Haemostasis, 2009, 101, 123-133.	3.4	39
123	Lack of association between aspirin responsiveness and seven candidate gene haplotypes in patients with symptomatic vascular disease. Thrombosis and Haemostasis, 2009, 101, 123-33.	3.4	15
124	Assessment of platelet function in the laboratory. Hamostaseologie, 2009, 29, 25-31.	1.9	9
125	Changes in the immature platelet fraction within ageing platelet concentrates. Journal of Thrombosis and Haemostasis, 2008, 6, 2213-2215.	3.8	10
126	The characterization and impact of microparticles on haemostasis within freshâ€frozen plasma. Vox Sanguinis, 2008, 95, 197-204.	1.5	54

#	Article	lF	Citations
127	"Message in the Platelet―– more than just vestigial mRNA!. Platelets, 2008, 19, 395-404.	2.3	71
128	Lack of reproducibility of assessment of aspirin responsiveness by optical aggregometry and two platelet function tests. Platelets, 2008, 19, 119-124.	2.3	67
129	Monitoring Antiplatelet Therapy. , 2008, , 125-158.		O
130	Measuring antiplatelet drug effects in the laboratory. Thrombosis Research, 2007, 120, 323-336.	1.7	171
131	Clinical Tests of Platelet Function. , 2007, , 445-474.		14
132	Platelet Counting. , 2007, , 475-483.		5
133	Continuing developments with the automated platelet count <sup>1</sup> . International Journal of Laboratory Hematology, 2007, 29, 77-91.	1.3	139
134	Platelet function analyzer (PFA)â€100® closure time in the evaluation of platelet disorders and platelet function. Journal of Thrombosis and Haemostasis, 2006, 4, 312-319.	3.8	382
135	Platelet function analyzer (PFA)-100R closure time in the evaluation of platelet disorders and platelet function: reply to a rebuttal. Journal of Thrombosis and Haemostasis, 2006, 4, 1432-1432.	3.8	9
136	Can the PFA-100R be modified to detect P2Y12 inhibition?. Journal of Thrombosis and Haemostasis, 2006, 4, 1424-1426.	3.8	19
137	Platelet function analyzer (PFA)-100Rclosure time in the evaluation of platelet disorders and platelet function: reply to a rebuttal. Journal of Thrombosis and Haemostasis, 2006, 4, 1433-1434.	3.8	12
138	Platelet hyperactivity and risk of recurrent thrombosis. Journal of Thrombosis and Haemostasis, 2006, 4, 2544-2546.	3.8	19
139	A review of inherited platelet disorders with guidelines for their management on behalf of the UKHCDO. British Journal of Haematology, 2006, 135, 603-633.	2.5	339
140	Prion protein in patients with renal failure. Transfusion Medicine, 2006, 16, 165-168.	1.1	4
141	Methods for counting platelets in severe thrombocytopenia. Psychophysiology, 2006, 5, 70-5.	1.1	4
142	Platelet hyper-function in acute coronary syndromes. Blood Coagulation and Fibrinolysis, 2005, 16, 557-562.	1.0	31
143	Platelet function analysis. Blood Reviews, 2005, 19, 111-123.	5.7	296
144	The expression of prion protein (PrPC) in the megakaryocyte lineage. Journal of Thrombosis and Haemostasis, 2005, 3, 1266-1273.	3.8	27

#	Article	IF	Citations
145	Current methods of assessing platelet function: relevance to transfusion medicine. Vox Sanguinis, 2005, 88, 153-163.	1.5	108
146	Platelet function (measured by Platelet Function Analyser - 100) and obstructive sleep apnoea. Journal of Sleep Research, 2005, 14, 325-327.	3.2	6
147	Accuracy of platelet counting haematology analysers in severe thrombocytopenia and potential impact on platelet transfusion. British Journal of Haematology, 2005, 128, 520-525.	2.5	132
148	The role of PFA-100R testing in the investigation and management of haemostatic defects in children and adults. British Journal of Haematology, 2005, 130, 3-10.	2.5	178
149	A highly unusual cluster of acute promyelocytic leukaemia: an environmental aetiology?. International Journal of Laboratory Hematology, 2005, 27, 71-73.	0.2	3
150	Impact of immunological platelet counting (by the platelet/RBC ratio) on haematological practice. Cytometry Part B - Clinical Cytometry, 2005, 67B, 1-5.	1.5	15
151	Increased platelet count and leucocyte-platelet complex formation in acute symptomatic compared with asymptomatic severe carotid stenosis. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 76, 1249-1254.	1.9	44
152	Screening for Aspirin Responsiveness After Transient Ischemic Attack and Stroke. Stroke, 2005, 36, 1001-1005.	2.0	162
153	Assessment of the antiplatelet effects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA. Platelets, 2005, 16, 269-280.	2.3	64
154	Platelet activation can occur by shear stress alone in the PFA-100 platelet analyser. Platelets, 2005, 16, 81-84.	2.3	14
155	Measurement of the Antiplatelet Effects of Aspirin in Cerebrovascular Disease. Stroke, 2004, 35, e146-7; author reply e146-7.	2.0	3
156	In Vitro Measurement of High-Shear Platelet Adhesion and Aggregation by the PFA-100 $<$ SUP $>$ $\hat{A}^{\otimes}$ $<$ /SUP $>$ . , 2004, 272, 215-224.		9
157	Platelet degranulation and monocyte–platelet complex formation are increased in the acute and convalescent phases after ischaemic stroke or transient ischaemic attack. British Journal of Haematology, 2004, 125, 777-787.	2.5	114
158	Circulating reticulated platelets in the early and late phases after ischaemic stroke and transient ischaemic attack. British Journal of Haematology, 2004, 126, 861-869.	2.5	87
159	Acute promyelocytic leukaemia presenting as postpartum haemorrhage. International Journal of Laboratory Hematology, 2004, 26, 233-237.	0.2	11
160	High incidence of defective high-shear platelet function among platelet donors. Transfusion, 2004, 44, 764-770.	1.6	25
161	Platelet Counting. , 2004, 272, 029-046.		17
162	Measuring platelet function?. The Hematology Journal, 2004, 5, S164-S169.	1.4	7

#	Article	IF	CITATIONS
163	The majority of cellular prion protein released from endothelial cells is soluble. Transfusion, 2003, 43, 677-678.	1.6	3
164	Factor viii assays in haemophilia a patients treated with refactoâ, ¢. British Journal of Haematology, 2003, 121, 379-380.	2.5	8
165	Activation of platelets in whole blood by recombinant factor VIIa by a thrombinâ€dependent mechanism. British Journal of Haematology, 2003, 122, 651-661.	2.5	15
166	Endothelial cells express normal cellular prion protein. British Journal of Haematology, 2003, 123, 372-373.	2.5	5
167	Interstitial white matter neurons express less reelin and are abnormally distributed in schizophrenia: towards an integration of molecular and morphologic aspects of the neurodevelopmental hypothesis. Molecular Psychiatry, 2003, 8, 769-769.	7.9	177
168	Relation between acute hypoxia and activation of coagulation in human beings. Lancet, The, 2003, 361, 2207-2208.	13.7	82
169	GPVI levels in platelets: relationship to platelet function at high shear. Blood, 2003, 102, 2811-2818.	1.4	113
170	The expression of prion protein by endothelial cells: a source of the plasma form of prion protein?. British Journal of Haematology, 2002, 119, 863-873.	2.5	34
171	The PFA- $100\hat{A}^{\odot}$ : a potential rapid screening tool for the assessment of platelet dysfunction. International Journal of Laboratory Hematology, 2002, 24, 225-232.	0.2	82
172	Increased non-transferrin bound iron in plasma-depleted SAG-M red blood cell units. Vox Sanguinis, 2002, 82, 122-126.	1.5	22
173	Comparison of glycocalicin, thrombopoietin and reticulated platelet measurement as markers of platelet turnover in HIV+ samples. Platelets, 2001, 12, 108-113.	2.3	12
174	Laboratory monitoring of antiplatelet therapy. , 2001, , 386-406.		1
175	The impact of oral anticoagulant therapy, factor VIII level and quality of factor V-deficient plasma on three commercial methods for activated protein C resistance. Blood Coagulation and Fibrinolysis, 2001, 12, 179-186.	1.0	13
176	Platelet Counting by the RBC/Platelet Ratio Method. American Journal of Clinical Pathology, 2001, 115, 460-464.	0.7	131
177	Advances in Platelet Counting. Hematology, 2001, 5, 421-427.	1.5	5
178	The storage defects in grey platelet syndrome and $\hat{l}\pm\hat{l}$ -storage pool deficiency affect $\hat{l}\pm$ -granule factor V and multimerin storage without altering their proteolytic processing. British Journal of Haematology, 2001, 113, 871-877.	2.5	23
179	Increased circulating platelet-leucocyte complexes and platelet activation in patients with antiphospholipid syndrome, systemic lupus erythematosus and rheumatoid arthritis. British Journal of Haematology, 2001, 115, 451-459.	2.5	217
180	An Interlaboratory Study of a Candidate Reference Method for Platelet Counting. American Journal of Clinical Pathology, 2001, 115, 448-459.	0.7	103

#	Article	lF	CITATIONS
181	Immunoplatelet counting: a proposed new reference procedure. British Journal of Haematology, 2000, 108, 228-235.	2.5	77
182	In vivo biotinylation studies: specificity of labelling of reticulated platelets by thiazole orange and mepacrine. British Journal of Haematology, 2000, 108, 859-864.	2.5	54
183	Expression of cell-associated prion protein on normal human platelets. British Journal of Haematology, 2000, 110, 748-749.	2.5	4
184	Two colour analysis of reticulated platelets. International Journal of Laboratory Hematology, 2000, 22, 211-213.	0.2	29
185	New quantitative parameters on a recently introduced automated blood cell counter - the XE 2100 <sup>TM</sup> . International Journal of Laboratory Hematology, 2000, 22, 345-350.	0.2	100
186	von Willebrand factorâ€eleaving protease activity in congenital thrombotic thrombocytopenic purpura. British Journal of Haematology, 2000, 111, 1215-1222.	2.5	3
187	Advances in platelet counting. British Journal of Haematology, 2000, 111, 733-744.	2.5	7
188	von Willebrand factor-cleaving protease activity in congenital thrombotic thrombocytopenic purpura. British Journal of Haematology, 2000, 111, 1215-1222.	2.5	81
189	Progress in the assessment of platelet function. British Journal of Haematology, 2000, 111, 733-44.	2.5	67
190	Platelet activation responses in vitro to human mast cell activation. British Journal of Haematology, 1999, 106, 208-215.	2.5	4
191	Performance of the platelet function analyser PFA-100?? in testing abnormalities of primary haemostasis. Blood Coagulation and Fibrinolysis, 1999, 10, 25-32.	1.0	157
192	Flow cytometric analysis of reticulated platelets: evidence for a large proportion of non-specific labelling of dense granules by fluorescent dyes. British Journal of Haematology, 1998, 100, 351-357.	2.5	91
193	Reticulated platelets in primary and reactive thrombocytosis. British Journal of Haematology, 1998, 101, 388-389.	2.5	14
194	Studies of multimerin in patients with von Willebrand disease and platelet von Willebrand factor deficiency. British Journal of Haematology, 1998, 103, 20-28.	2.5	6
195	Platelet activation and turnover in the primary antiphospholipid syndrome. Lupus, 1998, 7, 333-340.	1.6	30
196	Platelet activation markers and the primary antiphospholipid syndrome (PAPS). Lupus, 1998, 7, 48-51.	1.6	18
197	Reticulated platelets. Platelets, 1997, 8, 379-384.	2.3	70
198	Rapid flow cytometric quantitation of reticulated platelets in whole blood. Platelets, 1996, 7, 189-194.	2.3	25

#	Article	IF	CITATIONS
199	Relative reactivity of platelets from thrombopoietin- and interleukin-6- treated dogs. Blood, 1996, 87, 4158-4163.	1.4	48
200	14. Inhibition of the IL-6-mediated augmentation of fibrinogen by an anti-gp130 monoclonal antibody in vivo. Fibrinolysis, 1996, 10, 4-5.	0.5	0
201	Inhibition of the acute-phase response in vivo by anti-gp130 monoclonal antibodies. British Journal of Haematology, $1996, 95, 443-451$ .	2.5	9
202	Cytokine–Induced Alteration of Platelet and Hemostatic Function. Stem Cells, 1996, 14, 154-162.	3.2	65
203	Role of non-transferrin bound iron in iron overload and liver dysfunction in long term survivors of acute leukaemia and bone marrow transplantation Journal of Clinical Pathology, 1996, 49, 853-856.	2.0	64
204	Inhibition of the acute-phase response in vivo by anti-gp130 monoclonal antibodies. British Journal of Haematology, 1996, 95, 443-51.	2.5	2
205	Non-transferrin bound iron and neutropenia after cytotoxic chemotherapy Journal of Clinical Pathology, 1994, 47, 350-352.	2.0	42
206	Successful use of all-trans retinoic acid in acute promyelocytic leukaemia presenting during the second trimester of pregnancy. British Journal of Haematology, 1994, 86, 681-682.	2.5	52
207	Platelet α-granules. Blood Reviews, 1993, 7, 52-62.	5.7	529
208	Porcine platelets contain an increased quantity of ultra-high molecular weight von Willebrand factor and numerous alpha-granular tubular structures. British Journal of Haematology, 1993, 83, 608-615.	2.5	17
209	Quantitative and qualitative assessment of plasma von Willebrand factor in classic Kaposi's sarcoma. Journal of the American Academy of Dermatology, 1993, 28, 217-221.	1.2	4
210	Effect of Type IIB von Willebrand Disease Mutation Arg(545)Cys on Platelet Glycoprotein Ib Binding – Studies with Recombinant von Willebrand Factor. Thrombosis and Haemostasis, 1993, 70, 1058-1062.	3 <b>.</b> 4	17
211	Platelet Alpha-granular Fibrinogen. Platelets, 1992, 3, 1-10.	2.3	16
212	Absence of the gamma-Leu 427 (gamma') variant in the platelet alpha- granular fibrinogen pool supports the role of glycoprotein IIB/IIIA in mediating fibrinogen uptake into platelets/megakaryocytes [letter; comment]. Blood, 1992, 79, 3394-3395.	1.4	2
213	Red blood cells from patients with sickle cell disease exhibit an increased adherence to cultured endothelium pretreated with tumour necrosis factor (TNF). British Journal of Haematology, 1992, 81, 591-597.	2.5	44
214	The influence of therapeutic blocking of Gp IIb/IIIa on platelet αâ€granular fibrinogen. British Journal of Haematology, 1992, 82, 721-728.	2.5	22
215	Unique expression of von Willebrand factor by type IIA von Willebrand's disease endothelial cells. British Journal of Haematology, 1992, 81, 401-406.	2.5	3
216	Characterization of Three Mutations Causing von Willebrand Disease Type IIA in Five Unrelated Families. Thrombosis and Haemostasis, 1992, 67, 618-622.	3.4	16

#	Article	IF	CITATIONS
217	THE ORIGIN AND PHYSIOLOGICAL RELEVANCE OF αâ€GRANULE ADHESIVE PROTEINS. British Journal of Haematology, 1990, 74, 125-130.	2.5	52
218	Endothelium specific Weibel-Palade bodies in a continuous human cell line, EA.hy926. In Vitro Cellular & Developmental Biology, 1990, 26, 1167-1172.	1.0	112
219	Expression of Fibrinogen Receptors in Platelets of Migraine Patients –Correlation with GPIIb Content and Plasma Cholesterol – Reply. Thrombosis and Haemostasis, 1990, 63, 318.	3.4	2
220	Uncoordinated expression of alpha-granule proteins in human megakaryocytes. Progress in Clinical and Biological Research, 1990, 356, 131-42.	0.2	9
221	Uncoordinated expression of fibrinogen compared with thrombospondin and von Willebrand factor in maturing human megakaryocytes. Blood, 1989, 73, 1123-1129.	1.4	72
222	Comparison of the <i>in vitro</i> characteristics of von Willebrand factor in British and commercial factor VIII concentrates. British Journal of Haematology, 1989, 73, 100-104.	2.5	45
223	Uptake of plasma fibrinogen into the alpha granules of human megakaryocytes and platelets Journal of Clinical Investigation, 1989, 84, 1320-1324.	8.2	188
224	Chromatography of the VIII/VWF complex on dextran sulphate sepharose. Thrombosis Research, 1988, 50, 295-304.	1.7	7
225	Amaurosis fugax under the age of 40 years Journal of Neurology, Neurosurgery and Psychiatry, 1987, 50, 81-84.	1.9	44
226	Chromatography of vWF on dextran sulphate sepharose. Thrombosis Research, 1987, 48, 641-652.	1.7	2
227	The Vascular Function of Platelets. , 0, , 808-824.		0